---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-017328"
form_type: "8-K"
ticker: null
cik: "0001113148"
company_name: "INFINITY PHARMACEUTICALS, INC."
filed_at: "2023-04-07T23:59:59+00:00"
generated_at: "2026-06-17T04:27:57.069589+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Infinity Pharma receives second Nasdaq deficiency; market value below $50M

## Summary
- Received April 4, 2023 letter: market value of listed securities below $50M for 30 consecutive days (Minimum MVLS Requirement).
- Also non-compliant with total assets/revenue rule requiring at least $50M each for most recent fiscal year.
- Has 180 days, until October 2, 2023, to regain compliance via $50M+ market value close for 10 consecutive days.
- Already out of compliance with minimum $1.00 bid price rule since December 2022 (previously disclosed).
- Failure to comply by Oct 2 could lead to delisting; may appeal or apply to transfer to Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001140361-23-017328
- form_type: 8-K
- cik: 0001113148
- company_name: INFINITY PHARMACEUTICALS, INC.
- filed_at: 2023-04-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1113148/000114036123017328/0001140361-23-017328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1113148/000114036123017328/brhc10051174_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-017328
- JSON: https://secwatch.observer/filing/0001140361-23-017328.json
- Plain text: https://secwatch.observer/filing/0001140361-23-017328.txt

## Key facts
- Listing & Compliance Notices
  INFINITY PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5450(b)(2)(A), 5450(b)(3)(A)
  source text: April 4, 2023, Infinity Pharmaceuticals, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) for continued listing on the Nasdaq Global Select Market, as the market value of the Company’s listed securities was less than $50,000,000 for the previous 30 consecutive business days. The Staff also noted in its letter that the Company is not in compli
  evidence_url: https://www.sec.gov/Archives/edgar/data/1113148/000114036123017328/0001140361-23-017328-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.